Breaking barriers: harnessing hypofractionated radiotherapy to transform outcomes in low tumor mutation burden stage III non-small cell lung cancer - a retrospective study.

Front Immunol · 2025 · PMC12014550 · PMID 40270970

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

did not reach statistical significanceP=0.079so close (0.05 < p ≤ 0.1)

Although HFRT showed a marked advantage in PFS, the difference in OS between the HFRT and CFRT groups did not reach statistical significance (P=0.079), likely due to the limited sample size of this study.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.